METHODS OF REDUCING NEPHROTOXICITY IN SUBJECTS ADMINISTERED WITH NUCLEOSIDE PHOSPHONATES

• US 20160303147A1
• Filed: 04/13/2016
• Published: 10/20/2016
• Est. Priority Date: 04/27/2007
• Status: Abandoned Application

• Current Assignee: Chimerix Incorporated
• Original Assignee: Chimerix Incorporated
• Inventors: Painter, George R.
• Application Number:
  US15/098,011
• Publication Number:
  US 20160303147A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 31/685 one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 47/543 Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07F 9/6512 having the nitrogen atoms in positions 1 and 3
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conjugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.

Claims

1. A method for treating or preempting adenovirus infection in an immunodeficient human subject comprising administering to said subject a compound:

2. The method of claim 1, wherein said immunodeficient subject has previously experienced toxic side effects or nephrotoxicity from treatment with a compound selected from the group consisting of cidofovir, cyclic cidofovir, tenofovir, and adefovir.

3. The method of claim 1, wherein said immunodeficient subject has primary or acquired immunodeficiency.

4. The method of claim 3 wherein said immunodeficient subject has acquired immunodeficiency as a result of immunosuppressive therapy.

5. The method of claim 3, wherein said immunodeficient subject has acquired immunodeficiency as a result of cyclosporine treatment.

6. The method of claim 1, wherein said immunodeficient subject is a transplant patient.

7. The method of claim 6, wherein said immunodeficient subject is a renal transplant patient, a hepatic transplant patient, or a bone marrow transplant patient.

8. The method of claim 1, wherein said immunodeficient subject is suffering from chronic fatigue syndrome.

9. The method of claim 1, wherein the adenovirus infection is resistant to treatment with a compound selected from the group consisting of cidofovir, cyclic cidofovir, tenofovir, and adefovir.

10. The method of claim 1, wherein said immunodeficient subject is infected with one or more viruses in addition to adenovirus and the one or more viruses exhibits synergistic action with adenovirus.

11. The method of claim 1, wherein the adenovirus infection is resistant to valganciclovir hydrochloride or ganciclovir.

12. The method of claim 1, wherein said immunodeficient subject exhibits side effects to valganciclovir hydrochloride or ganciclovir.

13. The method of claim 1, wherein said compound is administered to said immunodeficient subject at a dosage of 20 up to 5000 μ

g/kg.

14. The method of claim 1, wherein said compound is administered daily, every other day, once a week, or once every two weeks.

15. The method of claim 1, wherein said compound is administered to said immunodeficient subject at a dosage of less than 5 mg/kg.